首页> 美国卫生研究院文献>Oncology Letters >Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents
【2h】

Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents

机译:未作特殊说明的未分化多形性肉瘤的异种移植模型对于治疗剂的临床前测试至关重要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Undifferentiated pleomorphic sarcoma not otherwise specified belongs to the heterogeneous group of soft tissue tumors. It is preferentially located in the upper and lower extremities of the body, and surgical resection remains the only curative treatment. Preclinical animal models are crucial to improve the development of novel chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma. However, this approach has been hampered by the lack of reproducible animal models. The present study established two xenograft animal models generated from stable non-clonal cell cultures, and investigated the difference in chemotherapeutic effects on tumor growth between undifferentiated pleomorphic sarcoma in vivo and in vitro. The cell cultures were generated from freshly isolated tumor tissues of two patients with undifferentiated pleomorphic sarcoma. For the in vivo analysis, these cells were injected subcutaneously into immunodeficient mice. The mice were monitored for tumor appearance and treated with the most common or innovative chemotherapeutic agents available to date. Furthermore, the same drugs were administered to in vitro cell cultures. The most effective tumor growth inhibition in vitro was observed with doxorubicin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA), also known as vorinostat. In the in vivo xenograft mouse model, the combination of doxorubicin and the tyrosine kinase inhibitor pazopanib induced a significant tumor reduction. By contrast, treatment with vorinostat did not reduce the tumor growth. Taken together, the results obtained from drug testing in vitro differed significantly from the in vivo results. Therefore, the novel and reproducible xenograft animal model established in the present study demonstrated that in vivo models are required to test potential chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma prior to clinical use, since animal models are more similar to humans, compared with in vitro cell cultures.
机译:除非另外说明,未分化的多形性肉瘤属于软组织肿瘤的异质性组。它优先位于身体的上,下肢,而手术切除仍是唯一的治疗方法。临床前动物模型对于改善新型化学治疗剂对未分化多形性肉瘤的治疗至关重要。但是,由于缺乏可复制的动物模型,这种方法受到了阻碍。本研究建立了由稳定的非克隆细胞培养物产生的两种异种移植动物模型,并研究了体内和体外未分化多形性肉瘤对肿瘤生长的化学治疗效果差异。细胞培养是从两名未分化的多形性肉瘤患者的新鲜分离的肿瘤组织中产生的。为了进行体内分析,将这些细胞皮下注射到免疫缺陷小鼠中。监测小鼠的肿瘤外观,并用迄今可用的最常见或创新的化学治疗剂治疗。此外,将相同的药物用于体外细胞培养。用阿霉素和组蛋白脱乙酰基酶抑制剂亚磺酰苯胺异羟肟酸(SAHA)(也称为伏立诺他)观察到最有效的体外肿瘤生长抑制作用。在体内异种移植小鼠模型中,阿霉素和酪氨酸激酶抑制剂帕唑帕尼的组合可显着减少肿瘤。相反,用伏立诺他治疗并没有减少肿瘤的生长。两者合计,从体外药物测试获得的结果与体内结果明显不同。因此,在本研究中建立的新颖且可重现的异种移植动物模型表明,在临床使用之前,由于动物模型与人相比,与动物更相似,因此需要体内模型来测试潜在的化学治疗剂以治疗未分化的多形性肉瘤。体外细胞培养。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号